A recent study showed cetuximab-resistant CRC tumors to have mutational hotspots located in the genomic landscapes of receptor tyrosine kinases (EGFR-ERBB2), RAS, and WNT pathways, and ERBB2 (HER2 gene) amplifications are observed in colon cancer (37–40). This evidence concerns the gene ERBB2 and malignant colon neoplasm.